CEBPZ and acute myeloid leukemia: Although no significant differences in OS or relapse-free survival were observed between the azacitidine and observation groups, our data suggest that risk-adapted MRD-guided maintenance strategies may benefit specific subgroups, particularly those with molecularly persistent CBF-AML.